Last Updated : July 24, 2024
Details
Generic Name:
omalizumab
Project Status:
Not filed
Therapeutic Area:
Chronic rhinosinusitis with nasal polyps
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
NS0026-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps inadequately controlled by intranasal corticosteroids alone.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024